Anticancer drug mithramycin interacts with core histones: An additional mode of action of the DNA groove binder
Mithramycin (MTR) is a clinically approved DNA-binding antitumor antibiotic currently in Phase 2 clinical trials at National Institutes of Health for treatment of osteosarcoma. In view of the resurgence in the studies of this generic antibiotic as a human medicine, we have examined the binding prope...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | FEBS Open Bio |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2211546314000965 |